Citius Pharmaceuticals, Inc. (CTXR) News
Track canonical SquawkNews coverage tagged to CTXR, Citius Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
CTXR: LYMPHIR launch drives early revenue and creates an investment arbitrage opportunity
Citius Pharmaceuticals and Citius Oncology have launched LYMPHIR for CTCL, achieving early revenue and broad payer coverage. The company reports strong clinical results, a robust pipeline, and highlights an investment op
EQUITY | Sep 09, 2026, 07:54 PM UTC
L
Citius Oncology (CTXR) reports fiscal Q3 2026 results, business update
Citius Oncology, Inc. (CTXR) reports fiscal third quarter 2026 financial results and provides a business update, according to TradeXchange Newsdesk.
EARNINGS | Aug 14, 2026, 08:30 PM UTC
L
Citius Oncology Expands Board
Citius Oncology appoints Jonathan Peri as independent director
MNA | Aug 12, 2026, 12:01 PM UTC
H
Citius Oncology Reports Strong Cancer Treatment Momentum
Citius Oncology sees strong commercial momentum
EQUITY | Aug 05, 2026, 01:17 PM UTC